Cheng Y, Zhu X, Linghu D, et al. - In this retrospective study, researchers contrasted the efficacy of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP). The date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12 months of follow‐up at the Eye Center in People’s Hospital of Peking University have been analyzed. A total of 283 eyes (145 infants) treated with conbercept and 916 eyes (480 infants) treated with ranibizumab were enrolled. No significant difference was found in the rate of retinal vascularization. Findings suggested that conbercept and ranibizumab provide appropriate treatment for ROP. Conbercept as opposed to ranibizumab resulted in less recurrence and longer periods of treatment.